| Genetics and pathogenesis of diffuse large B-cell lymphoma R Schmitz, GW Wright, DW Huang, CA Johnson, JD Phelan, JQ Wang, ... New England journal of medicine 378 (15), 1396-1407, 2018 | 1789 | 2018 |
| A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications GW Wright, DW Huang, JD Phelan, ZA Coulibaly, S Roulland, RM Young, ... Cancer cell 37 (4), 551-568. e14, 2020 | 757 | 2020 |
| A multiprotein supercomplex controlling oncogenic signalling in lymphoma JD Phelan, RM Young, DE Webster, S Roulland, GW Wright, M Kasbekar, ... Nature 560 (7718), 387-391, 2018 | 343 | 2018 |
| B-cell receptor signaling in diffuse large B-cell lymphoma RM Young, AL Shaffer III, JD Phelan, LM Staudt Seminars in hematology 52 (2), 77-85, 2015 | 230 | 2015 |
| Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens RM Young, T Wu, R Schmitz, M Dawood, W Xiao, JD Phelan, W Xu, ... Proceedings of the National Academy of Sciences 112 (44), 13447-13454, 2015 | 179 | 2015 |
| Pathogenic B‐cell receptor signaling in lymphoid malignancies: new insights to improve treatment RM Young, JD Phelan, WH Wilson, LM Staudt Immunological reviews 291 (1), 190-213, 2019 | 114 | 2019 |
| Targeting the HTLV-I-regulated BATF3/IRF4 transcriptional network in adult T cell leukemia/lymphoma M Nakagawa, AL Shaffer, M Ceribelli, M Zhang, G Wright, W Xiao, ... Cancer Cell 34 (2), 286-297. e10, 2018 | 101 | 2018 |
| Genome-wide screens identify lineage-and tumor-specific genes modulating MHC-I-and MHC-II-restricted immunosurveillance of human lymphomas D Dersh, JD Phelan, ME Gumina, B Wang, JH Arbuckle, J Holly, ... Immunity 54 (1), 116-131. e10, 2021 | 89 | 2021 |
| Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2 DJ Hodson, AL Shaffer, W Xiao, GW Wright, R Schmitz, JD Phelan, ... Proceedings of the National Academy of Sciences 113 (14), E2039-E2046, 2016 | 84 | 2016 |
| ATF3 is a novel regulator of mouse neutrophil migration ND Boespflug, S Kumar, JW McAlees, JD Phelan, HL Grimes, K Hoebe, ... Blood, The Journal of the American Society of Hematology 123 (13), 2084-2093, 2014 | 82 | 2014 |
| Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity CS Velu, A Chaubey, JD Phelan, SR Horman, M Wunderlich, ML Guzman, ... The Journal of clinical investigation 124 (1), 222-236, 2014 | 82 | 2014 |
| Growth factor independence 1 antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia C Khandanpour, JD Phelan, L Vassen, J Schütte, R Chen, SR Horman, ... Cancer cell 23 (2), 200-214, 2013 | 81 | 2013 |
| Gfi1–cells and circuits: unraveling transcriptional networks of development and disease JD Phelan, NF Shroyer, T Cook, B Gebelein, HL Grimes Current opinion in hematology 17 (4), 300-307, 2010 | 73 | 2010 |
| Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies JD Phelan, T Orekov, FD Finkelman The Journal of Immunology 180 (1), 44-48, 2008 | 66 | 2008 |
| Susceptibility to JRA/JIA: complementing general autoimmune and arthritis traits JD Phelan, SD Thompson, DN Glass Genes & Immunity 7 (1), 1-10, 2006 | 50 | 2006 |
| Distinct roles of Cdc42 in thymopoiesis and effector and memory T cell differentiation F Guo, S Zhang, P Tripathi, J Mattner, J Phelan, A Sproles, J Mo, ... PLoS One 6 (3), e18002, 2011 | 49 | 2011 |
| Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma N Thomas, K Dreval, DS Gerhard, LK Hilton, JS Abramson, RF Ambinder, ... Blood 141 (8), 904-916, 2023 | 44 | 2023 |
| Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma M Roschewski, JD Phelan, WH Wilson The Cancer Journal 26 (3), 195-205, 2020 | 35 | 2020 |
| Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14 J Choi, JD Phelan, GW Wright, B Häupl, DW Huang, AL Shaffer III, ... Proceedings of the National Academy of Sciences 117 (11), 6092-6102, 2020 | 34 | 2020 |
| SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma AC Wilke, C Doebele, A Zindel, KS Lee, SA Rieke, M Ceribelli, ... Blood, The Journal of the American Society of Hematology 139 (4), 538-553, 2022 | 32 | 2022 |
Louis M. StaudtNational Cancer InstituteVerified email at mail.nih.gov
